Inactive Instrument

Neon Therapeutics, Inc.

Equities

US64050Y1001

Biotechnology & Medical Research

Neon Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019

August 06, 2019 at 04:30 pm IST

Neon Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced operating loss was USD 22.315 million compared to USD 19.117 million a year ago. Net loss was USD 21.932 million compared to USD 18.899 million a year ago. Basic loss per share was USD 0.79 compared to USD 7.84 a year ago. For the half year, operating loss was USD 43.895 million compared to USD 35.874 million a year ago. Net loss was USD 42.956 million compared to USD 35.420 million a year ago. Basic loss per share was USD 1.55 compared to USD 17.05 a year ago.

Latest news about Neon Therapeutics, Inc.

Neon Therapeutics, Inc. Announces Management Changes	07/20/07	CI
Neon Therapeutics, Inc.(NasdaqGS:NTGN) dropped from S&P TMI Index	06/20/06	CI
BioNTech SE completed the acquisition of Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others.	06/20/06	CI
Transcript : Neon Therapeutics, Inc. - Shareholder/Analyst Call	04/20/04
Neon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	01/20/01	CI
Neon Therapeutics, Inc. Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01	30/20/30	CI
Neon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	02/20/02	CI
BioNTech SE entered into an Agreement to acquire Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others for $73.6 million.	16/20/16	CI
Neon Therapeutics, Inc. Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01	18/19/18	CI
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs; to Reduce Workforce by Approximately 24% of Current Headcount	21/19/21	CI
Neon Therapeutics Intends to Explore Strategic Alternatives	21/19/21	CI
Neon Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	12/19/12	CI
Neon Therapeutics, Inc. Presents Updated Data at the Society for Immunotherapy of Cancer's 34th Annual Meeting in National Harbor, MD	08/19/08	CI
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens	06/19/06	CI
Neon Therapeutics, Inc. Provides Business Update	06/19/06	CI
Neon Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	06/19/06	CI
Transcript : Neon Therapeutics, Inc. - Special Call	15/19/15
Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers	15/19/15	CI
Neon Therapeutics To Seek Acquisitions	01/19/01	CI
Transcript : Neon Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 05:01 PM	16/19/16
Neon Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Clinical Update	13/19/13	CI
Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer	08/19/08	CI
Neon Therapeutics, Inc. Presents Updated Data from Ongoing Phase 1B Nt-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01	01/19/01	CI
Neon Therapeutics, Inc. Reports Consolidated Financial Results for the Fourth Quarter and Twelve Months of 2018	11/19/11	CI
Neon Therapeutics to Present At the American Association for Cancer Research Annual Meeting	28/19/28	CI

Chart Neon Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs